The JAK1/2 inhibitor ruxolitinib can prevent CRS after treatment with anti-CD123 CAR T cells without hampering CAR T cell efficacy in a xenograft model by reducing inflammatory cytokines [105]. This evidence concerns the gene JAK1 and congenital rubella syndrome.